
The role of forecasting in supporting strategic management decisions in oncology, post-marketing surveillance and other strategic management issues are going to be the areas on which I shall be focusing in this blog.
(Dec 11, 2008)In 2007 the FDA was re-authorized with a significant new authority - the authority to require the establishment of Risk Evaluation and Mitigation Strategies - REMS. In a very short part of the reauthorization bill the entire world of marketing drugs in the USA was turned upside down - and not much has been said about it!
(Dec 19, 2008)Oncology is quite probably the most complex health care market, and modeling it has become an essential need for most players.
(Jan 9, 2009)I've been a bit quiet on the blogging front lately and I have good reason. A new acronym has appeared, and behind it lies a mechanism that will change the way in which health care in the USA is delivered - NHIN.
(Jul 30, 2009)Is it possible that what used to be called disease management programs could be migrating into a new world through the use of chronic illness programs with self-insured employers ?
(Mar 18, 2010)At long last it seems that the massive health reform bill is going to pass and, hidden among its many interesting aspects, is a subtle yet significant element. This bill requires that, in a few years time, all insurance companies shall use common paperwork and forms.
(Mar 25, 2010)An audience of more than 150 senior industry professionals will be witness to this meeting of minds, marking the beginning of the two day event at the Regents Park Marriott Hotel in London.
Andrew Tolve investigates the value of the Internet as a pharma marketing research medium
Often criticised for not properly adopting new web technologies, pharma proves it knows a thing or two about the corporate website.
Alex Gochtovtt, principal with Cognizant’s enterprise analytics practice, discusses pharma’s social media opportunities and the importance of data analytics
An interview with Serkan Erkovan of Boehringer Ingelheim.
Ashok Bhaseen, Vice President of Sales & Marketing at Pediapharm reveals how his company establishes trust when engaging KOLs